Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

BACKGROUND: The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. METHODS: In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical su...

Full description

Saved in:
Bibliographic Details
Published in:N Engl J Med
Main Authors: Bajorin, D.F., Witjes, J.A., Gschwend, J.E., Schenker, M., Valderrama, B.P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S.F., Park, S.H., Ye, D., Agerbaek, M., Enting, D., McDermott, R., Gajate, P., Peer, A., Milowsky, M.I., Nosov, A., Antonio, J. Neif, Tupikowski, K., Toms, L., Fischer, B.S., Qureshi, A., Collette, S., Unsal-Kacmaz, K., Broughton, E., Zardavas, D., Koon, H.B., Galsky, M.D.
Format: Artigo
Language:Inglês
Published: 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215888/
https://ncbi.nlm.nih.gov/pubmed/34077643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2034442
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items